Elmutaz Mohammed Shaikho

Elmutaz Mohammed Shaikho

Auto-generated profile, based on publicly available information

Elmutaz Mohammed Shaikho

Department of Medicine Boston University School of Medicine Boston Massachusetts 02118

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2017 in BMC Genomics
Verified
Journal Article
Open access
PDF file
ESElmutaz M. Shaikho
Elmutaz M. Shaikho
JFJohn Farrell
John Farrell
AAAbdulrahman Alsultan
Abdulrahman Alsultan
HQHatem Qutub
Hatem Qutub
AAAmein K. Al-Ali
Amein K. Al-Ali
MSMartin H Steinberg
Martin H Steinberg
Sickle cell anemia causes severe complications and premature death. Five common β-globin gene cluster haplotypes are each associated with characteristic fetal hemoglobin (HbF) levels. As HbF is the major modulator of disease severity, classifying patients according to haplotype is useful. The first method of haplotype classification used restriction fragment length polymorphisms (RFLPs) to detect single nucleotide polymorphisms (SNPs) in the β-globin gene cluster. This is labor intensive, and error prone. We used genome-wide SNP data imputed to the 1000 Genomes reference panel to obtain phased data distinguishing parental alleles. We successfully haplotyped 813 sickle cell anemia patients previously classified by RFLPs with a concordance >98%. Four SNPs (rs3834466, rs28440105, rs10128556, and rs968857) marking four different restriction enzyme sites unequivocally defined most haplotypes. We were able to assign a haplotype to 86% of samples that were either partially or misclassified using RFLPs. Phased data using only four SNPs allowed unequivocal assignment of a haplotype that was not always possible using a larger number of RFLPs. Given the availability of genome-wide SNP data, our method is rapid and does not require high computational resources.

1 April 2017 in Stem Cell Reports
Verified
Journal Article
Open access
SPSeonmi Park
Seonmi Park
AGAndreia Gianotti-Sommer
Andreia Gianotti-Sommer
FMFrancisco Javier Molina-Estevez
Francisco Javier Molina-Estevez
KVKim Vanuytsel
Kim Vanuytsel
NSNick Skvir
Nick Skvir
GMGeorge J. Murphy
George J. Murphy
Sickle cell anemia affects millions of people worldwide and is an emerging global health burden. As part of a large NIH-funded NextGen Consortium, we generated a diverse, comprehensive, and fully characterized library of sickle-cell-disease-specific induced pluripotent stem cells (iPSCs) from patients of different ethnicities, β-globin gene (HBB) haplotypes, and fetal hemoglobin (HbF) levels. iPSCs stand to revolutionize the way we study human development, model disease, and perhaps eventually, treat patients. Here, we describe this unique resource for the study of sickle cell disease, including novel haplotype-specific polymorphisms that affect disease severity, as well as for the development of patient-specific therapeutics for this phenotypically diverse disorder. As a complement to this library, and as proof of principle for future cell- and gene-based therapies, we also designed and employed CRISPR/Cas gene editing tools to correct the sickle hemoglobin (HbS) mutation.

24 July 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
AHAlawi H. Habara
Alawi H. Habara
ESElmutaz M. Shaikho
Elmutaz M. Shaikho
MSMartin H Steinberg
Martin H Steinberg
Fetal hemoglobin (HbF) has well‐known tempering effects on the symptoms of sickle cell disease and its levels vary among patients with different haplotypes of the sickle hemoglobin gene. Compared with sickle cell anemia haplotypes found in patients of African descent, HbF levels in Saudi and Indian patients with the Arab‐Indian (AI) haplotype exceed that in any other haplotype by nearly twofold. Genetic association studies have identified some loci associated with high HbF in the AI haplotype but these observations require functional confirmation. Saudi patients with the Benin haplotype have HbF levels almost twice as high as African patients with this haplotype but this difference is unexplained. Hydroxyurea is still the only FDA approved drug for HbF induction in sickle cell disease. While most patients treated with hydroxyurea have an increase in HbF and some clinical improvement, 10 to 20% of adults show little response to this agent. We review the genetic basis of HbF regulation focusing on sickle cell anemia in Saudi Arabia and discuss new drugs that can induce increased levels of HbF.

13 June 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
ESElmutaz M. Shaikho
Elmutaz M. Shaikho
JFJohn J. Farrell
John J. Farrell
AAAbdulrahman Alsultan
Abdulrahman Alsultan
PSPaola Sebastiani
Paola Sebastiani
MSMartin H Steinberg
Martin H Steinberg

22 October 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
YDYan Dai
Yan Dai
ESElmutaz M. Shaikho
Elmutaz M. Shaikho
JPJessica Perez
Jessica Perez
CWCarolyn A. Wilson
Carolyn A. Wilson
LLLesley Y. Liu
Lesley Y. Liu
MSMartin H Steinberg
Martin H Steinberg
Key Points: BCL2L1 is associated with HbF gene activation.

1 July 2016 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
ESElmutaz M. Shaikho
Elmutaz M. Shaikho
AHAlawi H. Habara
Alawi H. Habara
AAAbdulrahman Alsultan
Abdulrahman Alsultan
AAA.M. Al-Rubaish
A.M. Al-Rubaish
FAFahad Al-Muhanna
Fahad Al-Muhanna
MSMartin H Steinberg
Martin H Steinberg